Clinical trials recruiting for Cutaneous Melanoma
27
Recruiting trials
31
US states with sites
13
Countries
4%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 3 |
| Nivolumab | 2 |
| Opdualag | 2 |
| 177Lu-RAD204 | 1 |
| AU-007 | 1 |
| Aldesleukin | 1 |
| Avelumab | 1 |
| Avutometinib | 1 |
| Bevacizumab | 1 |
| Binimetinib | 1 |
| Cemiplimab | 1 |
| Chemotherapy (dacarbazine or temozolomide) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 9 |
| Texas | 9 |
| Florida | 7 |
| Michigan | 6 |
| New York | 6 |
| Ohio | 6 |
| Tennessee | 6 |
| Colorado | 5 |
| Pennsylvania | 5 |
| Massachusetts | 4 |
| Minnesota | 3 |
| New Jersey | 3 |
Top cities
Houston, Texas 7New York, New York 6Nashville, Tennessee 5San Francisco, California 5Boston, Massachusetts 4Cleveland, Ohio 4Denver, Colorado 4Philadelphia, Pennsylvania 4Detroit, Michigan 3Fairfax, Virginia 3
Self-screener
Recruiting trials
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- ACTengine® IMA203 Combined With mRNA-4203
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria
- NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
- Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
- Neoadjuvant Combination Immunotherapy for Stage III Melanoma
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
- Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
- The MELAcare Study: A New Method for Surveillance of Melanoma Patients
Related conditions
Trials recruiting for Cutaneous Melanoma often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Lung cancer 2180Non-small cell lung cancer 507Mucosal Melanoma 8Colorectal cancer 1359Breast cancer 2239Type 2 diabetes 891Solid Tumor, Adult 38Soft Tissue Sarcoma (STS) 4Renal cell carcinoma 28
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Cutaneous Melanoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.